Crinetics Pharmaceuticals (CRNX) Financials

$33.86 +0.10 (+0.29%)

As of 11:10 AM Eastern

Annual Income Statements for Crinetics Pharmaceuticals

This table shows Crinetics Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-6.02	-9.16	-27	-50	-74	-108	-164	-215	-298
Consolidated Net Income / (Loss)	-6.02	-9.16	-27	-50	-74	-108	-164	-215	-298
Net Income / (Loss) Continuing Operations	-6.02	-9.16	-27	-50	-74	-108	-164	-215	-298
Total Pre-Tax Income	-6.02	-9.16	-27	-50	-74	-108	-164	-215	-298
Total Operating Income	-6.04	-9.13	-29	-54	-75	-108	-168	-223	-339
Total Gross Profit	0.59	2.05	2.43	1.19	0.14	1.08	4.74	4.01	1.04
Total Revenue	0.59	2.05	2.43	1.19	0.14	1.08	4.74	4.01	1.04
Operating Revenue	0.59	2.05	2.43	1.19	0.14	1.08	4.74	4.01	1.04
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	6.63	11	31	55	75	109	173	227	340
Selling, General & Admin Expense	1.53	1.94	6.66	14	18	25	42	58	100
Research & Development Expense	5.10	9.23	24	42	57	84	130	169	240
Total Other Income / (Expense), net	0.03	-0.03	1.60	3.41	0.99	0.16	3.96	8.08	40
Interest & Investment Income	0.04	0.03	1.75	3.46	0.99	0.16	3.31	8.24	41
Other Income / (Expense), net	-0.00	-0.05	-0.15	-0.05	0.00	0.00	0.66	-0.16	-0.52
Basic Earnings per Share	($5.96)	($6.68)	($2.23)	($2.09)	($2.42)	($2.80)	($3.15)	($3.69)	($3.69)
Weighted Average Basic Shares Outstanding	1.01M	1.37M	12.14M	24.18M	30.45M	38.44M	51.98M	58.07M	80.78M
Diluted Earnings per Share	($5.96)	($6.68)	($2.23)	($2.09)	($2.42)	($2.80)	($3.15)	($3.69)	($3.69)
Weighted Average Diluted Shares Outstanding	1.01M	1.37M	12.14M	24.18M	30.45M	38.44M	51.98M	58.07M	80.78M
Weighted Average Basic & Diluted Shares Outstanding	1.01M	1.37M	12.14M	24.18M	30.45M	38.44M	53.91M	69.60M	93.05M

This table shows Crinetics Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-42	-45	-46	-51	-57	-61	-67	-74	-75	-83
Consolidated Net Income / (Loss)	-42	-45	-46	-51	-57	-60	-67	-74	-77	-81
Net Income / (Loss) Continuing Operations	-42	-45	-46	-51	-57	-60	-67	-74	-77	-81
Total Pre-Tax Income	-42	-45	-46	-51	-57	-60	-67	-74	-77	-81
Total Operating Income	-43	-48	-48	-53	-59	-63	-74	-83	-88	-95
Total Operating Expenses	44	48	51	54	59	63	74	83	88	95
Selling, General & Admin Expense	12	11	12	13	15	17	21	25	26	28
Research & Development Expense	32	37	38	41	44	46	53	58	62	67
Total Other Income / (Expense), net	1.53	2.57	1.98	2.02	1.52	2.56	7.07	8.73	11	14
Interest & Investment Income	1.50	1.90	2.04	2.11	1.57	2.52	6.85	8.74	11	14
Basic Earnings per Share	($0.78)	($0.83)	($0.85)	($0.94)	($1.01)	($0.89)	($0.93)	($0.94)	($0.96)	($0.86)
Weighted Average Basic Shares Outstanding	53.77M	51.98M	53.91M	54.28M	56.81M	58.07M	72.29M	79.01M	80.09M	80.78M
Diluted Earnings per Share	($0.78)	($0.83)	($0.85)	($0.94)	($1.01)	($0.89)	($0.93)	($0.94)	($0.96)	($0.86)
Weighted Average Diluted Shares Outstanding	53.77M	51.98M	53.91M	54.28M	56.81M	58.07M	72.29M	79.01M	80.09M	80.78M
Weighted Average Basic & Diluted Shares Outstanding	53.81M	53.91M	54.03M	54.69M	66.80M	69.60M	78.86M	80.04M	92.74M	93.05M

This table details how cash moves in and out of Crinetics Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-5.71	2.04	31	-4.65	53	108	-167	22	210
Net Cash From Operating Activities	-5.47	-9.48	-19	-46	-62	-89	-115	-166	-226
Net Cash From Continuing Operating Activities	-5.47	-9.48	-19	-46	-62	-89	-115	-166	-226
Net Income / (Loss) Continuing Operations	-6.02	-9.16	-27	-50	-74	-108	-164	-215	-298
Consolidated Net Income / (Loss)	-6.02	-9.16	-27	-50	-74	-108	-164	-215	-298
Depreciation Expense	0.09	0.13	0.47	0.89	0.95	0.92	0.98	1.10	2.79
Amortization Expense	-	-	-0.43	-1.23	-0.23	0.42	0.03	-6.27	-15
Non-Cash Adjustments To Reconcile Net Income	0.27	0.27	2.32	6.52	11	17	29	45	73
Changes in Operating Assets and Liabilities, net	0.19	-0.72	5.30	-2.13	0.38	1.10	19	8.04	12
Net Cash From Investing Activities	-0.19	-0.30	-119	42	0.22	-56	-174	-200	-575
Net Cash From Continuing Investing Activities	-0.19	-0.30	-119	42	0.22	-56	-174	-200	-575
Purchase of Property, Plant & Equipment	-0.19	-0.30	-1.06	-0.49	-0.19	-0.44	-1.66	-4.69	-3.84
Purchase of Investments	-	-	-118	-108	-136	-125	-330	-528	-1,147
Sale and/or Maturity of Investments	-	-	0.00	150	136	69	157	337	576
Net Cash From Financing Activities	-0.05	12	170	0.07	115	253	122	389	1,010
Net Cash From Continuing Financing Activities	-0.05	12	170	0.07	115	253	122	389	1,010
Repayment of Debt	-0.05	-0.21	-	-	-	0.00	-	-	0.00
Issuance of Common Equity	-	-	106	0.00	114	250	117	369	970
Other Financing Activities, net	-	0.07	0.45	0.13	0.29	3.14	4.72	20	40

This table details how cash moves in and out of Crinetics Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-31	1.76	8.52	-1.64	103	-88	341	-94	15	-53
Net Cash From Operating Activities	-38	-35	-41	-46	-41	-39	-53	-46	-63	-65
Net Cash From Continuing Operating Activities	-39	-35	-41	-46	-41	-39	-53	-46	-63	-65
Net Income / (Loss) Continuing Operations	-42	-45	-46	-51	-57	-60	-67	-74	-77	-81
Consolidated Net Income / (Loss)	-42	-45	-46	-51	-57	-60	-67	-74	-77	-81
Depreciation Expense	0.25	0.28	0.28	0.28	0.27	0.26	0.47	0.75	0.77	0.79
Amortization Expense	-0.13	-0.35	-0.53	-0.91	-1.25	-3.58	-3.85	-3.41	-3.51	-4.16
Non-Cash Adjustments To Reconcile Net Income	7.51	7.49	6.21	10	12	17	15	20	19	20
Changes in Operating Assets and Liabilities, net	-4.21	2.37	-0.69	-4.42	4.85	8.30	2.69	11	-2.15	-0.31
Net Cash From Investing Activities	6.82	37	49	31	-193	-87	0.31	-54	21	-542
Net Cash From Continuing Investing Activities	6.82	37	49	31	-193	-87	0.31	-54	21	-542
Purchase of Property, Plant & Equipment	-0.68	-0.27	-0.02	-0.24	-3.50	-0.94	-1.33	-0.96	-0.53	-1.03
Purchase of Investments	-49	-34	-23	-59	-278	-168	-100	-192	-130	-725
Sale and/or Maturity of Investments	56	71	71	91	88	87	101	139	151	184
Net Cash From Financing Activities	1.08	0.12	0.48	13	338	38	394	5.50	57	554
Net Cash From Continuing Financing Activities	1.08	0.12	0.48	13	338	38	394	5.50	57	554
Issuance of Common Equity	-0.01	-	0.00	11	329	29	383	-4.31	47	544
Other Financing Activities, net	1.09	0.12	0.48	1.35	8.92	9.17	10	9.81	11	9.54

This table presents Crinetics Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2017	2019	2020	2021	2022	2023	2024
Period end date	12/31/2017	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	16	130	183	351	352	635	1,435
Total Current Assets	15	123	177	345	345	574	1,375
Cash & Equivalents	14	40	93	201	33	55	265
Restricted Cash	-	-	-	-	-	0.00	0.50
Short-Term Investments	-	78	78	133	302	504	1,090
Prepaid Expenses	0.97	4.95	6.61	11	11	16	21
Plant, Property, & Equipment, net	0.40	3.95	3.18	2.83	3.50	11	12
Total Noncurrent Assets	0.03	3.09	2.77	3.47	3.49	50	47
Long-Term Investments	-	-	-	1.01	0.00	0.47	0.00
Other Noncurrent Operating Assets	0.03	3.09	2.77	2.46	3.49	50	47
Total Liabilities & Shareholders' Equity	16	130	183	351	352	635	1,435
Total Liabilities	0.92	13	15	19	36	96	110
Total Current Liabilities	0.90	8.34	10	16	28	44	60
Accounts Payable	0.40	5.50	5.59	8.47	15	23	21
Accrued Expenses	0.18	2.12	4.07	6.59	9.08	15	29
Current Deferred Revenue	-	-	-	0.00	2.24	2.06	2.18
Other Current Liabilities	-	0.72	0.84	0.94	1.05	4.17	7.15
Total Noncurrent Liabilities	0.02	4.90	4.04	3.08	8.13	52	50
Noncurrent Deferred Revenue	0.02	-	-	0.00	6.10	4.75	4.70
Other Noncurrent Operating Liabilities	-	4.85	4.01	3.07	2.02	48	45
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-15	117	169	332	316	539	1,325
Total Preferred & Common Equity	-15	117	169	332	316	539	1,325
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-15	117	169	332	316	539	1,325
Common Stock	1.24	211	337	608	759	1,192	2,276
Retained Earnings	-16	-94	-168	-275	-439	-654	-952
Accumulated Other Comprehensive Income / (Loss)	-	0.15	0.03	-0.38	-3.93	0.98	0.96

This table presents Crinetics Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	385	314	293	642	978	936	937
Total Current Assets	378	305	285	576	917	875	878
Cash & Equivalents	31	41	40	143	396	302	317
Short-Term Investments	337	255	225	412	505	561	545
Prepaid Expenses	9.96	9.28	20	21	16	12	15
Plant, Property, & Equipment, net	3.56	3.27	3.22	9.76	12	12	12
Total Noncurrent Assets	2.99	5.34	5.22	56	49	49	48
Long-Term Investments	0.00	-	-	4.67	0.00	0.00	0.00
Other Noncurrent Operating Assets	2.99	5.34	5.22	51	49	49	48
Total Liabilities & Shareholders' Equity	385	314	293	642	978	936	937
Total Liabilities	34	34	39	94	103	105	104
Total Current Liabilities	25	26	33	40	52	54	54
Accounts Payable	13	16	21	22	29	24	18
Accrued Expenses	7.72	6.83	8.60	13	15	20	26
Current Deferred Revenue	2.32	2.12	2.08	1.66	2.46	2.56	1.69
Other Current Liabilities	1.02	1.08	1.11	3.99	5.79	7.45	7.41
Total Noncurrent Liabilities	8.95	7.36	6.53	53	51	50	51
Noncurrent Deferred Revenue	6.65	5.62	5.07	5.14	4.74	4.32	5.20
Other Noncurrent Operating Liabilities	2.30	1.74	1.46	48	47	46	46
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	351	280	254	548	875	831	833
Total Preferred & Common Equity	351	280	254	548	875	831	833
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	351	280	254	548	875	831	833
Common Stock	751	768	792	1,142	1,595	1,626	1,702
Retained Earnings	-394	-485	-536	-594	-721	-795	-872
Accumulated Other Comprehensive Income / (Loss)	-5.01	-2.51	-1.71	-0.87	0.15	-0.19	2.04

This table displays calculated financial ratios and metrics derived from Crinetics Pharmaceuticals' official financial filings.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	247.20%	18.73%	-50.86%	-88.10%	659.15%	339.42%	-15.28%	-74.11%
EBITDA Growth	0.00%	-51.97%	-218.61%	-88.11%	-36.90%	-43.28%	-56.27%	-37.14%	-54.22%
EBIT Growth	0.00%	-51.78%	-214.58%	-86.68%	-39.11%	-43.69%	-55.27%	-33.21%	-52.34%
NOPAT Growth	0.00%	-51.01%	-214.56%	-87.50%	-39.24%	-43.69%	-55.88%	-32.60%	-52.22%
Net Income Growth	0.00%	-52.13%	-196.11%	-85.96%	-46.39%	-45.83%	-52.28%	-30.88%	-39.10%
EPS Growth	0.00%	-12.08%	66.62%	6.28%	-15.79%	-15.70%	-12.50%	-17.14%	0.00%
Operating Cash Flow Growth	0.00%	-73.35%	-105.29%	-138.35%	-33.73%	-42.82%	-30.05%	-44.36%	-35.88%
Free Cash Flow Firm Growth	0.00%	0.00%	-185.26%	-85.76%	-42.08%	-44.09%	-37.03%	-50.70%	-47.63%
Invested Capital Growth	0.00%	0.00%	-100.00%	0.00%	-56.50%	-41.41%	-552.61%	-10.07%	-49.43%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	1,418.31%	-23.40%	-15.01%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	-6,361.43%	-17,009.34%	-9.21%	-11.02%	-8.84%	-10.24%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-9.23%	-10.59%	-7.35%	-10.63%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-9.23%	-11.02%	-7.28%	-10.46%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-9.29%	-9.48%	-7.57%	-7.38%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-2.19%	-5.00%	-1.65%	0.81%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-21.92%	-19.10%	-4.18%	-8.53%	-11.96%	-2.03%	-13.09%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-1,931.36%	-8.26%	-15.35%	-2.21%	-15.63%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	41.72%	-592.71%	-1,146.42%	-6.52%	-72.07%	-0.26%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-1,010.70%	-442.40%	-1,187.19%	-4,545.18%	-52,276.06%	-9,866.23%	-3,508.72%	-5,680.04%	-33,832.44%
Operating Margin	-1,026.15%	-446.31%	-1,182.45%	-4,512.32%	-52,783.80%	-9,990.91%	-3,544.06%	-5,547.17%	-32,613.47%
EBIT Margin	-1,026.32%	-448.66%	-1,188.76%	-4,516.51%	-52,783.80%	-9,990.91%	-3,530.19%	-5,551.13%	-32,663.43%
Profit (Net Income) Margin	-1,021.90%	-447.78%	-1,116.76%	-4,226.49%	-51,980.28%	-9,985.25%	-3,460.38%	-5,345.85%	-28,720.69%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	99.80%	100.09%	100.00%	100.00%	100.00%
Interest Burden Percent	99.57%	99.80%	93.94%	93.58%	98.68%	99.85%	98.02%	96.30%	87.93%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-2,629.18%	-8,270.37%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-2,590.17%	-8,171.47%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	2,504.41%	7,900.91%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-124.77%	-369.46%	-86.09%	-51.61%	-42.98%	-50.57%	-50.16%	-32.02%
Cash Return on Invested Capital (CROIC)	0.00%	-2,829.18%	-8,070.37%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	-58.82%	-370.09%	-82.66%	-47.77%	-40.30%	-47.56%	-45.12%	-32.79%
Return on Assets (ROA)	0.00%	-58.71%	-347.67%	-77.35%	-47.04%	-40.28%	-46.62%	-43.45%	-28.83%
Return on Common Equity (ROCE)	0.00%	127.70%	378.12%	-86.09%	-51.61%	-42.98%	-50.57%	-50.16%	-32.02%
Return on Equity Simple (ROE_SIMPLE)	0.00%	60.96%	0.00%	-43.04%	-43.70%	-32.43%	-51.82%	-39.79%	-22.52%
Net Operating Profit after Tax (NOPAT)	-4.23	-6.39	-20	-38	-52	-75	-118	-156	-237
NOPAT Margin	-718.30%	-312.42%	-827.72%	-3,158.63%	-36,948.66%	-6,993.64%	-2,480.84%	-3,883.02%	-22,829.43%
Net Nonoperating Expense Percent (NNEP)	0.00%	-39.01%	-98.90%	-21.52%	-14.76%	-12.76%	-13.87%	-13.14%	-6.40%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-37.15%	-28.90%	-17.90%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	260.27%	94.82%	274.26%	1,133.19%	12,694.37%	2,275.05%	894.95%	1,447.65%	9,599.33%
R&D to Revenue	865.87%	451.49%	1,008.20%	3,479.13%	40,139.44%	7,815.86%	2,749.10%	4,199.53%	23,114.15%
Operating Expenses to Revenue	1,126.15%	546.31%	1,282.45%	4,612.32%	52,728.17%	10,099.81%	3,644.06%	5,647.17%	32,713.47%
Earnings before Interest and Taxes (EBIT)	-6.05	-9.18	-29	-54	-75	-108	-167	-223	-339
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-5.95	-9.05	-29	-54	-74	-106	-166	-228	-352
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	5.19	2.75	4.07	3.11	3.56	2.08
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	5.19	2.75	4.07	3.11	3.56	2.08
Price to Revenue (P/Rev)	173.17	49.88	296.90	509.42	3,271.37	1,251.83	207.88	477.97	2,652.90
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	241.79	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	57.46	296.90	410.18	2,067.99	941.33	137.28	338.66	1,349.17
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-0.97	-0.97	-1.01	-1.01	-1.01	-1.03	-1.04	-1.03
Leverage Ratio	0.00	1.06	1.06	1.11	1.10	1.07	1.08	1.15	1.11
Compound Leverage Factor	0.00	1.06	1.00	1.04	1.08	1.07	1.06	1.11	0.98
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	202.34%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-102.34%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	64.35	0.00	26.24	17.65	41.47	14.26	10.37	14.46
Noncontrolling Interest Sharing Ratio	0.00%	202.34%	202.34%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	16.91	0.00	14.79	16.92	21.55	12.45	13.07	23.04
Quick Ratio	0.00	15.82	0.00	14.20	16.29	20.86	12.06	12.71	22.69
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-6.87	-20	-36	-52	-75	-102	-154	-227
Operating Cash Flow to CapEx	-2,877.89%	-3,118.09%	-1,837.49%	-9,427.03%	-33,347.85%	-20,318.35%	-6,956.82%	-3,547.50%	-5,878.51%
Free Cash Flow to Firm to Interest Expense	0.00	-859.36	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-497.09	-1,184.88	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-514.36	-1,222.88	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.13	0.31	0.02	0.00	0.00	0.01	0.01	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	5.11	0.00	0.00	0.04	0.36	1.50	0.56	0.09
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	0.49	0.00	-1.25	-1.96	-2.77	-18	-20	-30
Invested Capital Turnover	0.00	8.42	9.99	-1.90	-0.09	-0.46	-0.45	-0.21	-0.04
Increase / (Decrease) in Invested Capital	0.00	0.49	-0.49	-1.25	-0.71	-0.81	-15	-1.82	-9.85
Enterprise Value (EV)	0.00	118	721	489	294	1,015	650	1,359	1,402
Market Capitalization	102	102	721	608	465	1,349	985	1,918	2,756
Book Value per Share	$0.00	($10.96)	$0.00	$4.84	$5.13	$6.99	$5.88	$8.07	$14.29
Tangible Book Value per Share	$0.00	($10.96)	$0.00	$4.84	$5.13	$6.99	$5.88	$8.07	$14.29
Total Capital	0.00	15	0.00	117	169	332	316	539	1,325
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-14	0.00	-118	-171	-335	-334	-559	-1,355
Capital Expenditures (CapEx)	0.19	0.30	1.06	0.49	0.19	0.44	1.66	4.69	3.84
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	0.08	0.00	-3.39	-3.88	-4.98	-17	-28	-39
Debt-free Net Working Capital (DFNWC)	0.00	14	0.00	115	167	329	317	530	1,316
Net Working Capital (NWC)	0.00	14	0.00	115	167	329	317	530	1,316
Net Nonoperating Expense (NNE)	1.79	2.77	7.02	13	21	32	46	59	61
Net Nonoperating Obligations (NNO)	0.00	-14	0.00	-118	-171	-335	-334	-559	-1,355
Total Depreciation and Amortization (D&A)	0.09	0.13	0.04	-0.34	0.72	1.34	1.02	-5.17	-12
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	3.72%	0.00%	-284.41%	-2,730.28%	-462.15%	-358.12%	-706.30%	-3,740.62%
Debt-free Net Working Capital to Revenue	0.00%	697.70%	0.00%	9,639.48%	117,607.75%	30,493.97%	6,701.73%	13,212.33%	126,631.76%
Net Working Capital to Revenue	0.00%	697.70%	0.00%	9,639.48%	117,607.75%	30,493.97%	6,701.73%	13,212.33%	126,631.76%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($5.96)	($6.68)	($2.23)	$0.00	($2.42)	($2.80)	($3.15)	($3.69)	($3.69)
Adjusted Weighted Average Basic Shares Outstanding	1.01M	1.37M	24.10M	0.00	33.03M	47.78B	51.98M	58.07M	80.78M
Adjusted Diluted Earnings per Share	($5.96)	($6.68)	($2.23)	$0.00	($2.42)	($2.80)	($3.15)	($3.69)	($3.69)
Adjusted Weighted Average Diluted Shares Outstanding	1.01M	1.37M	24.10M	0.00	33.03M	47.78B	51.98M	58.07M	80.78M
Adjusted Basic & Diluted Earnings per Share	($5.96)	($6.68)	($2.23)	$0.00	($2.42)	($2.80)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.01M	1.37M	12.14M	0.00	30.45M	38.44M	53.91M	69.60M	93.05M
Normalized Net Operating Profit after Tax (NOPAT)	-4.23	-6.39	-20	-38	-52	-75	-118	-156	-237
Normalized NOPAT Margin	-718.30%	-312.42%	-827.72%	-3,158.63%	-36,948.66%	-6,993.64%	-2,480.84%	-3,883.02%	-22,829.43%
Pre Tax Income Margin	-1,021.90%	-447.78%	-1,116.76%	-4,226.49%	-52,085.92%	-9,976.35%	-3,460.38%	-5,345.85%	-28,720.69%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-549.55	-1,146.88	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-384.62	-798.61	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-566.82	-1,184.88	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-401.89	-836.61	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Crinetics Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	-34.23%	-14.44%	125.06%	-24.45%	0.00%	-76.11%	-59.62%	-100.00%	0.00%
EBITDA Growth	-57.44%	-56.32%	-45.05%	-25.99%	-38.55%	-38.53%	-59.47%	-59.08%	-50.95%	-48.71%
EBIT Growth	-56.17%	-53.96%	-41.90%	-23.33%	-35.94%	-31.76%	-53.26%	-55.97%	-48.80%	-51.21%
NOPAT Growth	-56.27%	-53.96%	-41.83%	-23.12%	-35.72%	-31.76%	-53.26%	-56.21%	-48.87%	-51.21%
Net Income Growth	-50.53%	-46.10%	-32.83%	-20.30%	-37.05%	-33.58%	-45.52%	-45.27%	-33.71%	-34.11%
EPS Growth	-6.85%	-22.06%	-16.44%	-16.05%	-29.49%	-7.23%	-9.41%	0.00%	4.95%	3.37%
Operating Cash Flow Growth	-49.88%	-53.75%	-200.66%	-63.48%	-7.43%	-9.40%	-29.81%	0.26%	-51.97%	-67.92%
Free Cash Flow Firm Growth	31.91%	13.67%	-325.66%	-384.79%	-254.77%	-134.00%	-19.38%	26.22%	7.18%	-34.34%
Invested Capital Growth	-6,511.32%	-552.61%	5.71%	53.39%	31.87%	-10.07%	-64.82%	-209.13%	-156.46%	-49.43%
Revenue Q/Q Growth	4.33%	54.80%	277.86%	-63.12%	-64.98%	0.00%	0.00%	-37.66%	-100.00%	0.00%
EBITDA Q/Q Growth	-1.58%	-9.97%	-1.26%	-11.39%	-11.70%	-9.96%	-16.55%	-11.12%	-6.00%	-8.33%
EBIT Q/Q Growth	-0.88%	-9.51%	-0.89%	-10.65%	-11.20%	-6.15%	-17.35%	-12.60%	-6.08%	-7.87%
NOPAT Q/Q Growth	-0.95%	-9.44%	-0.89%	-10.46%	-11.29%	-6.24%	-17.35%	-12.59%	-6.06%	-7.91%
Net Income Q/Q Growth	1.06%	-7.31%	-2.23%	-10.84%	-12.71%	-4.59%	-11.37%	-10.65%	-3.74%	-4.90%
EPS Q/Q Growth	3.70%	-6.41%	-2.41%	-10.59%	-7.45%	11.88%	-4.49%	-1.08%	-2.13%	10.42%
Operating Cash Flow Q/Q Growth	-37.54%	8.50%	-15.65%	-12.32%	9.61%	6.83%	-37.23%	13.70%	-37.72%	-2.95%
Free Cash Flow Firm Q/Q Growth	-30.16%	-36.48%	-92.27%	-41.93%	4.75%	9.98%	1.91%	12.28%	-19.84%	-30.29%
Invested Capital Q/Q Growth	23.95%	-6.52%	12.74%	34.06%	-11.17%	-72.07%	-30.67%	-23.67%	7.77%	-0.26%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	100.00%	100.00%	0.00%	0.00%
EBITDA Margin	-9,456.11%	-6,717.49%	-1,800.11%	-5,436.94%	-17,341.91%	0.00%	-12,015.94%	-21,416.29%	0.00%	0.00%
Operating Margin	-9,487.77%	-6,707.48%	-1,790.89%	-5,363.87%	-17,045.38%	0.00%	-11,488.91%	-20,747.62%	0.00%	0.00%
EBIT Margin	-9,481.44%	-6,707.48%	-1,790.89%	-5,373.08%	-17,060.69%	0.00%	-11,488.91%	-20,750.88%	0.00%	0.00%
Profit (Net Income) Margin	-9,153.93%	-6,345.70%	-1,716.87%	-5,159.82%	-16,606.36%	0.00%	-10,457.81%	-18,560.15%	0.00%	0.00%
Tax Burden Percent	100.00%	99.89%	100.12%	100.00%	100.00%	99.91%	100.38%	100.00%	100.00%	99.69%
Interest Burden Percent	96.55%	94.71%	95.75%	96.03%	97.34%	96.00%	90.68%	89.44%	87.47%	85.33%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-54.95%	-50.57%	-60.09%	-57.44%	-44.36%	-50.16%	-40.76%	-47.66%	-40.26%	-32.02%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-197.34%	-90.37%	-23.71%	-72.65%	-156.97%	0.00%	-35.10%	-46.78%	0.00%	0.00%
Return on Assets (ROA)	-190.52%	-85.49%	-22.73%	-69.77%	-152.79%	0.00%	-31.95%	-41.84%	0.00%	0.00%
Return on Common Equity (ROCE)	-54.95%	-50.57%	-60.09%	-57.44%	-44.36%	-50.16%	-40.76%	-47.66%	-40.26%	-32.02%
Return on Equity Simple (ROE_SIMPLE)	-42.61%	0.00%	-62.53%	-72.36%	-36.41%	0.00%	-26.91%	-31.12%	-33.36%	0.00%
Net Operating Profit after Tax (NOPAT)	-30	-33	-34	-37	-41	-44	-51	-58	-61	-66
NOPAT Margin	-6,641.44%	-4,695.23%	-1,253.62%	-3,754.71%	-11,931.76%	0.00%	-8,042.23%	-14,523.33%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-4.10%	-3.50%	-4.03%	-4.13%	-3.49%	-3.63%	-2.58%	-2.86%	-2.16%	-1.49%
Return On Investment Capital (ROIC_SIMPLE)	-	-10.52%	-	-	-	-8.14%	-	-	-	-5.01%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	2,603.71%	1,590.13%	454.98%	1,350.51%	4,475.14%	0.00%	3,254.38%	6,225.06%	0.00%	0.00%
R&D to Revenue	6,984.06%	5,217.35%	1,435.91%	4,113.36%	12,670.23%	0.00%	8,334.53%	14,622.56%	0.00%	0.00%
Operating Expenses to Revenue	9,587.77%	6,807.48%	1,890.89%	5,463.87%	17,145.38%	0.00%	11,588.91%	20,847.62%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-43	-48	-48	-53	-59	-63	-74	-83	-88	-95
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-43	-48	-48	-54	-60	-66	-77	-85	-91	-98
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.00	3.11	3.09	3.82	2.93	3.56	2.88	2.91	3.31	2.08
Price to Tangible Book Value (P/TBV)	3.00	3.11	3.09	3.82	2.93	3.56	2.88	2.91	3.31	2.08
Price to Revenue (P/Rev)	170.72	207.88	202.05	200.96	339.53	477.97	1,278.36	1,743.38	2,651.34	2,652.90
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	111.15	137.28	132.94	146.24	221.08	338.66	821.94	1,120.31	1,821.05	1,349.17
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.03	-1.03	-1.06	-1.05	-1.03	-1.04	-1.04	-1.04	-1.03	-1.03
Leverage Ratio	1.09	1.08	1.11	1.12	1.14	1.15	1.12	1.13	1.14	1.11
Compound Leverage Factor	1.05	1.03	1.06	1.07	1.11	1.11	1.01	1.01	1.00	0.95
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	18.22	15.39	13.84	12.78	9.67	11.20	14.45	13.40	15.28	15.02
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	15.41	12.45	11.60	8.73	14.23	13.07	17.72	16.09	16.38	23.04
Quick Ratio	15.00	12.06	11.25	8.11	13.71	12.71	17.40	15.87	16.11	22.69
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-13	-18	-35	-49	-47	-42	-41	-36	-43	-56
Operating Cash Flow to CapEx	-5,642.08%	-12,849.27%	-254,487.50%	-19,297.47%	-1,181.11%	-4,119.25%	-3,968.17%	-4,776.65%	-11,898.30%	-6,285.13%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.02	0.01	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	1.91	1.50	1.44	1.52	0.71	0.56	0.26	0.18	0.10	0.09
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-17	-18	-16	-10	-12	-20	-26	-32	-30	-30
Invested Capital Turnover	-0.74	-0.45	-0.26	-0.30	-0.33	-0.21	-0.09	-0.07	-0.05	-0.04
Increase / (Decrease) in Invested Capital	-17	-15	0.96	12	5.41	-1.82	-10	-22	-18	-9.85
Enterprise Value (EV)	687	650	570	707	1,044	1,359	1,623	1,552	1,892	1,402
Market Capitalization	1,056	985	866	971	1,603	1,918	2,523	2,415	2,755	2,756
Book Value per Share	$6.54	$5.88	$5.20	$4.70	$10.02	$8.07	$12.57	$10.53	$10.41	$14.29
Tangible Book Value per Share	$6.54	$5.88	$5.20	$4.70	$10.02	$8.07	$12.57	$10.53	$10.41	$14.29
Total Capital	351	316	280	254	548	539	875	831	833	1,325
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-368	-334	-296	-265	-559	-559	-901	-863	-863	-1,355
Capital Expenditures (CapEx)	0.68	0.27	0.02	0.24	3.50	0.94	1.33	0.96	0.53	1.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-15	-17	-17	-12	-19	-28	-36	-43	-39	-39
Debt-free Net Working Capital (DFNWC)	354	317	279	252	535	530	865	820	824	1,316
Net Working Capital (NWC)	354	317	279	252	535	530	865	820	824	1,316
Net Nonoperating Expense (NNE)	12	12	12	14	16	16	15	16	15	14
Net Nonoperating Obligations (NNO)	-368	-334	-296	-265	-559	-559	-901	-863	-863	-1,355
Total Depreciation and Amortization (D&A)	0.12	-0.07	-0.25	-0.63	-0.97	-3.32	-3.37	-2.66	-2.74	-3.38
Debt-free, Cash-free Net Working Capital to Revenue	-236.01%	-358.12%	-397.67%	-255.05%	-409.91%	-706.30%	-1,798.38%	-3,072.49%	-3,719.25%	-3,740.62%
Debt-free Net Working Capital to Revenue	5,720.68%	6,701.73%	6,513.00%	5,217.21%	11,336.23%	13,212.33%	43,843.01%	59,234.58%	79,309.43%	126,631.76%
Net Working Capital to Revenue	5,720.68%	6,701.73%	6,513.00%	5,217.21%	11,336.23%	13,212.33%	43,843.01%	59,234.58%	79,309.43%	126,631.76%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.78)	($0.83)	($0.85)	($0.94)	($1.01)	($0.89)	($0.93)	($0.94)	($0.96)	($0.86)
Adjusted Weighted Average Basic Shares Outstanding	53.77M	51.98M	53.91M	54.28M	56.81M	58.07M	72.29M	79.01M	80.09M	80.78M
Adjusted Diluted Earnings per Share	($0.78)	($0.83)	($0.85)	($0.94)	($1.01)	($0.89)	($0.93)	($0.94)	($0.96)	($0.86)
Adjusted Weighted Average Diluted Shares Outstanding	53.77M	51.98M	53.91M	54.28M	56.81M	58.07M	72.29M	79.01M	80.09M	80.78M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	53.81M	53.91M	54.03M	54.69M	66.80M	69.60M	78.86M	80.04M	92.74M	93.05M
Normalized Net Operating Profit after Tax (NOPAT)	-30	-33	-34	-37	-41	-44	-51	-58	-61	-66
Normalized NOPAT Margin	-6,641.44%	-4,695.23%	-1,253.62%	-3,754.71%	-11,931.76%	0.00%	-8,042.23%	-14,523.33%	0.00%	0.00%
Pre Tax Income Margin	-9,153.93%	-6,352.75%	-1,714.82%	-5,159.82%	-16,606.36%	0.00%	-10,418.59%	-18,560.15%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Crinetics Pharmaceuticals' Financials

When does Crinetics Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Crinetics Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Crinetics Pharmaceuticals' net income changed over the last 8 years?

Crinetics Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$298.41 million in 2024, rising from -$6.02 million in 2016. The previous period was -$214.53 million in 2023. See Crinetics Pharmaceuticals' forecast for analyst expectations on what’s next for the company.

What is Crinetics Pharmaceuticals's operating income?

Crinetics Pharmaceuticals's total operating income in 2024 was -$338.85 million, based on the following breakdown:

Total Gross Profit: $1.04 million
Total Operating Expenses: $339.89 million

How has Crinetics Pharmaceuticals revenue changed over the last 8 years?

Over the last 8 years, Crinetics Pharmaceuticals' total revenue changed from $589 thousand in 2016 to $1.04 million in 2024, a change of 76.4%.

How much debt does Crinetics Pharmaceuticals have?

Crinetics Pharmaceuticals' total liabilities were at $109.79 million at the end of 2024, a 14.1% increase from 2023, and a 11,833.4% increase since 2017.

How much cash does Crinetics Pharmaceuticals have?

In the past 6 years, Crinetics Pharmaceuticals' cash and equivalents has ranged from $14.19 million in 2017 to $264.55 million in 2024, and is currently $264.55 million as of their latest financial filing in 2024.

How has Crinetics Pharmaceuticals' book value per share changed over the last 8 years?

Over the last 8 years, Crinetics Pharmaceuticals' book value per share changed from 0.00 in 2016 to 14.29 in 2024, a change of 1,428.6%.

Related Companies

This page (NASDAQ:CRNX) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Crinetics Pharmaceuticals (CRNX) Financials

Frequently Asked Questions About Crinetics Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Crinetics Pharmaceuticals (CRNX) Financials

Annual Income Statements for Crinetics Pharmaceuticals

Quarterly Income Statements for Crinetics Pharmaceuticals

Annual Cash Flow Statements for Crinetics Pharmaceuticals

Quarterly Cash Flow Statements for Crinetics Pharmaceuticals

Annual Balance Sheets for Crinetics Pharmaceuticals

Quarterly Balance Sheets for Crinetics Pharmaceuticals

Annual Metrics and Ratios for Crinetics Pharmaceuticals

Quarterly Metrics and Ratios for Crinetics Pharmaceuticals

Frequently Asked Questions About Crinetics Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools